Femme et Homme
- | Pays :
- Belgium
- | Organes : -
- | Spécialités : -
Extrait
An open-label, Phase II clinical study to evaluate the efficacy and safety of lanreotide autogel 90mg every 4 weeks in the treatment of symptomatic polycystic liver disease, including a dose escalation at month 6 to lanreotide autogel 120mg for non responders.
Critère d'inclusion
- Polycystic Liver Disease